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Sedation in Critically Ill Patients
By: Jason Haney, PharmD
PGY2 Critical Care Resident
Many critically ill patients experience agitation and anxiety in
the intensive care unit (ICU) setting. It has been reported that up
to 70% of patients in an ICU experience at least 1 episode of
agitation.1 Patient distress is inherently multifactorial and can
ultimately lead to increased
complications and a longer ICU
length of stay.1-3 The goals of
providing patient-directed ICU
care include adequate sedation to
enhance comfort and provide
relief from anxiety and agitation.2
Prior to initiating sedation, it is
important to conduct a thorough
patient assessment. Potential factors for causing anxiety should
be considered (Table 1) and any
reversible sources of patient distress should be removed or
treated.1-3 Healthcare providers
should assess for these confounding factors upon patient
admission and continue to evaluate for withdrawal symptoms.1,2

Medication reconciliation and a
thorough patient history are fundamental components of the initial
evaluation of the patient.1,2 A patient’s home medications, or the
lack thereof, may lead to significant adverse effects and/or drug
interactions.1,3 Anxiolytics, analgesics, antidepressants, antipsychotics, and other medications,
including herbal products, can
cause significant withdrawal or
rebound of chronic disease symptoms if withheld for even short
periods of time.1,2 Furthermore,
alcohol and elicit drugs may cause
similar symptoms of agitation during the acute detoxification and
withdrawal phases.1,2 However, if
it is not possible to attain a patient
history on admission, it should be
completed as soon as possible
through patient or family interview.
Sedation treatment goals should
be established by the healthcare
team to guide drug dosing and to
help avoid excessive sedation.2

Table 1. Factors Causing ICU Agitation and Anxiety1-3
Pain
Hypoxemia
Medications
Hypoglycemia
Mechanical ventilation Hypotension
Oral and nasal tubes
Underlying medical conditions
Invasive interventions
Immobility
Substance withdrawal
Turning/rolling

Suctioning
Room temperature
Delirium
Sleep deprivation
− Ambient light
− Noise
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Table 2. Riker Sedation-Agitation Scale (SAS)1
Score

Description

7

Dangerous agitation

6

Very agitated

5

Agitated

4

Calm and cooperative

3

Sedated

2

Very sedated

1

Unarousable

Definition
Pulling endotracheal tube (ETT), trying to remove catheters, climbing over bedrail, striking
at staff, thrashing from side-to-side
Does not calm despite frequent verbal reminding of limits, requires physical restraints,
biting ETT
Anxious or mildly agitated, attempting to sit up, calms to verbal instructions
Calm, awakens easily, follows commands
Difficult to arouse, awakens to verbal stimuli or gentle shaking but drifts off again, follows
simple commands
Arouses to physical stimuli but does not communicate or follow commands, may
move spontaneously
Minimal or no response to noxious stimuli, does not communicate or follow commands

The need for sedation varies between patients and fluctuates over
time; thus, the level of sedation
requires frequent reassessment.1,2
For example, an individual sedation requirement may increase
dramatically once the patient is
switched to a more stressful form
of mechanical ventilation. Higher
levels of sedation and possibly
neuromuscular blockade may then
be needed to achieve adequate sedation for ventilator synchrony.2
As the patient clinically improves,
sedation requirements should be
reassessed and decreased accordingly. A common sedation target
is a calm patient who is easily
aroused with maintenance of the
normal sleep-wake cycle, except
when deeper sedation is required
as previously mentioned.1
Once treatment goals are established, patients should be evaluated using a clinically validated
scale. A variety of scales have
been developed, validated, and
tested for inter-rater variability.1-4
A gold standard ICU sedation
scale has not been established, but
the Riker Sedation-Agitation
Scale (SAS) was the first sedation
scale proven to be reliable and
valid in critically ill patients
(Table 2).1,3 At MUSC, the SAS

is most commonly used with a
target score of 4. The Ramsay
Sedation Scale, Motor Activity
Assessment Scale (MAAS), and
Richmond
Agitation-Sedation
Scale (RASS) are examples of
other validated scales that may
be used.1-4
Sedation evaluation using a validated scale is essential to patient
treatment. Patient distress causes
metabolic changes that result in
tissue ischemia, fluid and electrolyte disturbances, and decreased wound healing.3 Failure
to achieve adequate sedation allows many patients to recall
frightening or unpleasant ICU
memories that contribute to
symptoms of post-traumatic
stress disorder (PTSD).1,3 In
contrast, unnecessarily prolonged and excessive sedation
has been shown to increase ICU
length of stay and a number of
complications.1,2 Patient evaluation should include an assessment of the following: level of
consciousness, ability to arouse,
cognition, pain, and agitation.2
It is important to combine the
sedation scale assessment with
clinical judgment and experience. Not all anxious patients

will exhibit normal signs of anxiety and agitation; instead, some
patients may be fearful and withdrawn.1 Objective sedation assessment is recommended for
deeply sedated patients, such as
those treated with therapeutic neuromuscular blockade or a pentobarbital-induced coma.1,2
Heart rate variability, loweresophageal contractility, and electroencephalogram signals processed by algorithms such as the
bispectral index (BIS) are commonly used to evaluate sedation in
critically ill patients due to the
lack of specificity and sensitivity
of vital sign assessment.1,2 Subjective and objective assessment
allow the titration of sedatives to
goal while avoiding inadequate
and excessive sedation.
The keys to managing anxiety are
listed in Table 3.1
Sedation
should be started only after providing sufficient analgesia to control pain.1,2 Patients that require
frequent reloading and/or particularly high infusion rates should be
reassessed for pain control and
delirium.1,2,5 Opioid analgesics
provide some sedation, but they
do not reduce awareness or have
an amnestic effect.1 Therefore,
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the majority of patients will require sedative therapy to control
anxiety and limit the amount of
unpleasant memories.
Sedation should be provided intermittently or on an as needed basis.1,2 Continuous sedation has
been associated with longer periods of sedation and ICU length of
stay.1 However, a scheduled daily
interruption of sedation (DIS), or
“sedation vacation,” should be
provided in situations requiring
continuous sedation for optimal
patient treatment in order to avoid
excessive and prolonged effects.2
Sedatives should also be used judiciously and only to the extent
required to achieve the established
sedation goal.1 Federal regulations have established that seda-

Table 3. ICU Anxiety Management1,2
Patient assessment
− Identify potential causes of anxiety
− Remove or treat reversible sources
− Complete patient history/medication reconciliation
Monitoring
− Define treatment goals
− Assess pain and sedation
− Identify delirium
Management
− Frequently reorient the patient
− Maintain patient comfort and optimize the environment
− Select medications based on patient characteristics, need for rapid
onset/offset of action, duration of therapy, and prior response
− Provide analgesia, then sedation
− Titrate medications to goal with the lowest effective dose
− Provide daily “sedation vacations” (if possible)
− Treat delirium and remove precipitating factors
De-escalation of therapy

tion is neither intended to be a
method of restraint nor to be
“used as a means of coercion,
discipline, convenience, or retaliation by staff.”6 Further-

Table 4. Pharmacology of Sedative-hypnotics1,2,5,7
Onset/
Unique Adverse
Drug
Effects
Duration
Lorazepam
5-20 min/ Acidosis and renal
failure at high
6-8 hr
doses due to the
solvents

more, excessive sedation has
been shown to be an independent
risk factor for delirium, which
increases the incidence of PTSD
and long-term mortality.2 Fortu-

Dosing

Comments

Daily
Cost
$$

Intermittent
0.02-0.06 mg/kg
every 2-6 hr
(start at 50% if
patient > 65
years)
0.02-0.08 mg/kg
every 0.5-2 hr

Continuous
0.01-0.1 mg/kg/hr

0.04-0.2 mg/kg/hr

Active metabolite
(renal elimination)

$$$

Longer
half-life,

Midazolam

2-5 min/
1-4 hr

N/A

Diazepam

2-5 min/
>12 hr

Phlebitis

0.03-0.1 mg/kg
every 0.5-6 hr

N/A

Active metabolite

$

Propofol

30-50 sec/
3-10 min

Elevated triglycerides, pancreatitis,
propofol infusion
syndrome, zinc
depletion

N/A

5-150 mcg/kg/min
(>40 mcg/kg/min
requires MD approval)

Contains egg &
soy products

$$$$

Dexmedetomidine

2-15 min/
6 min

Dystonia

N/A

0.5-1 mcg/kg over
10 min, then
0.2-0.7 mcg/kg/hr
up to 24 hr

Not FDA-approved
for use >24 hr,
some analgesic
properties

$$$$$

Haloperidol

3-20 min/
6-24 hr

QT interval
prolongation,
extrapyramidal
symptoms

0.03-0.15 mg/kg
every 0.5-6 hr

0.04-0.15 mg/kg/hr

Active metabolite

$$
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nately, analgesia and sedation
act synergistically and allow for
reduced dosing of both medications.1,2
Sedative-hypnotic agents should
be selected based on patient and
medication characteristics (ie,
drug allergies, organ dysfunction, active metabolites), the
need for rapid onset/offset of
action, expected duration of therapy, and prior response.1,2 A
variety of these agents exist,
such as benzodiazepines, propofol, and α2-agonists.1-3 The commonly used sedative-hypnotic
agents at MUSC are listed in Table 4 along with some of their
key characteristics.1,2,7
Benzodiazepines
Benzodiazepines have both sedative and hypnotic effects that
beneficially produce anterograde, but not retrograde, amnesia.1 Additionally, benzodiazepines can suppress the patient’s
anticipatory pain response; thus,
providing a synergistic opioidsparing effect.1
Diazepam may be used for acute
agitation and in rare instances
for long-term sedation, but it is
generally avoided due to the
long half-life of its active metabolite.1,7 Lorazepam and midazolam are the most commonly
used benzodiazepines for ICU
sedation.1,2
Midazolam has a rapid onset and
short duration of action, which
makes it preferable for treating
acutely
agitated
patients.1,2
However, midazolam accumulates and causes prolonged sedation in obese patients, as well as
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patients with hypoalbuminemia,
renal failure, or liver failure.1,2
Additionally, midazolam has
significant drug interactions due
to its metabolism via cytochrome P450 isoenzyme 3A4
and has unpredictable effects
reported with infusions longer
than 48-72 hours.1,2 Because of
these reasons, midazolam is only
recommended for short-term
(less than 48 hours) sedation.1,2
Lorazepam is metabolized via
glucuronidation; therefore, has
fewer potential drug interactions
than midazolam.1 In patients
with renal or hepatic insufficiency, lorazepam is preferred
over midazolam.1,8 Lorazepam
is also recommended for patients
requiring prolonged sedation;
however, it is not ideal for the
treatment of acute agitation due
to a slower onset of action.1,2
Lorazepam is particularly difficult to titrate due to its elimination half-life (12-15 hours).1
Loading doses should be given
by intravenous push to supplement a scheduled dosing regimen.1,5 A continuous infusion
should be started only after the
patient fails at least 3 scheduled
doses of lorazepam.5 Caution is
warranted since prolonged highrate infusions have resulted in
serious complications.1,2,8 Propylene glycol (PG) is used as a
solvent in various lorazepam formulations due to its poor solubility.1,2,8 PG has been associated
with causing reversible acute
tubular necrosis, osmol gap lactic acidosis, and hyperosmolarity
in patients receiving lorazepam
at doses exceeding 18 mg/hr for
greater than four weeks or 25
mg/hr for hours to days.1,2,8

Therefore, intermittent or continuous infusions up to 10 mg/hr
are recommended.
Propofol (Diprivan®)
Propofol is a general anesthetic
agent with favorable sedative,
hypnotic, anticonvulsant, antiemetic, and intracranial pressure
(ICP)-lowering
properties.1,7
However, like the benzodiazepines, propofol lacks any analgesic
properties.1,7 Propofol has a
rapid onset of action due to its
ability to cross the blood brain
barrier within minutes and short
duration of activity.1,2,7 Consequently, propofol is preferred in
patients that require rapid awakening for neurological assessments.1
Although propofol appears to be
an ideal sedative, it is more
costly than benzodiazepines and
has many potential complications. Propofol is manufactured
as a phospholipid emulsion,
which provides 1.1 kcal/mL of
fat. This must be considered in
the patient’s nutritional assessment.1,7 Due to the phospholipid
vehicle, long-term or high-dose
propofol infusions may cause
hypertriglyceridemia and/or pancreatitis.1,7
Additionally, the
phospholipid emulsion requires a
dedicated intravenous line due to
drug compatibility issues.1,7
Propofol is contraindicated in
patients with egg or soy allergies.1,7
Dose-dependent hypotension, bradycardia and lactic
acidosis may occur, as well as
propofol infusion syndrome.1,2,7
Propofol infusion syndrome is
associated with rhabdomyolysis,
metabolic
acidosis,
hepatomegaly, renal failure, and car-
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diac failure with high-dose infusions (>5 mg/kg/hr).2,5,9 Due to
the various potential complications with long-term therapy, the
Society of Critical Care Medicine
recommends limiting propofol
infusions to less than 48 hours.1,2
Dexmedetomidine (Precedex®)
Dexmedetomidine is a selective
α2-adrenergic receptor agonist
with sedative, analgesic, anxiolytic, and sympatholytic properties.2,7 Dexmedetomidine is a
relatively new option for ICU sedation but remains restricted to
specific indications due to its limited data, potential safety concerns, and significantly higher acquisition cost.2,5,9 The MUSC
Critical Care Committee recently
updated the guidelines for dexmedetomidine use and has finalized a pre-printed order form.5
Currently, it is only FDAindicated for the sedation of initially intubated and mechanically
ventilated patients for up to 24
hours.2,10 Dexmedetomidine has a
short half-life and almost immediate onset, making it a second-line
agent to propofol in patients requiring frequent neurological assessments.2,9,10 Dexmedetomidine
would be beneficial to allow for
cooperative sedation in patients
who cannot tolerate propofol (eg,
propofol infusion syndrome, hypertriglyceridemia) or are obese
with a redistribution phenomenon
of propofol.2
Dexmedetomidine lacks the respiratory depressant effects seen with
other sedative-hypnotic agents;
therefore, may decrease mechanical ventilation time.2,9,10 However, there are also disadvantages
of its use. Dexmedetomidine may

Pharmacy & Therapeutics Update

cause bradycardia and hypertension after initial bolus injections
due to vasoconstrictive effects.2,10
Hypotension potentially occurs with continuous
infusions as vasoconstriction
shifts to vasodilation as a result
of central sympatholysis.2,10
Dexmedetomidine should be
used cautiously in patients with
low ventricular ejection fraction
(≤ 30 %) or heart block due to
the potential for severe bradycardia and cardiac arrhythmias.2,10
Of note, dystonic reactions have
also been reported with dexmedetomidine use.2
Multiple patient factors can
cause anxiety, as well as influence the duration and intensity
of effects of sedative-hypnotics
(Table 1).1,2 Parent drug and
active metabolites can lead to
adverse or prolonged sedation
effects in patients with at least
one of these confounding factors. Elderly patients and those
with renal or hepatic dysfunction
may require an initial dosage
reduction depending on the
choice of sedative-hypnotic
agent.1,2 Consequently, sedatives must be individually dosed
and titrated from recommended
starting doses to optimize patient
sedation.1,2 Managing patient
sedation by following a structured approach with sedation
protocols facilitates sedative

dosing.
Sedation protocols that incorporate a validated scale are the key
to sedation management as they
have been shown to decrease the
amount of adverse effects, time of
mechanical ventilation, duration
of ICU and hospital length of stay,
incidence of ICU-related medical
complications, and hospitalization
costs.2 An effective sedation protocol provides titration strategies
for specific sedation targets, offers
guidance for daily interruption of
sedation, outlines a step-wise approach to transitioning from intermittent to continuous therapy, and
ensures that reversible causes of
agitation and anxiety are identified and treated.1,2 The MUSC
sedation protocol is adapted from
the Society of Critical Care Medicine guidelines, and is available
on the Clinicians Orders Forms
page under Critical Care or at:
http://www.musc.edu/cce/ORDFR
MS/CriticalCare/indexcriticalcare.
htm.1,5
Patients treated with sedativehypnotics for longer than 1 week
may develop physiological dependence, which can cause withdrawal symptoms if these agents
are rapidly discontinued (Table
5).1,2,9
Withdrawal has been
shown to lead to further complications and increased sedation requirements.1,2 Therefore, detailed

Table 5. Signs and Symptoms of Sedative Withdrawal2
Dysphoria
Increased sensitivity to light and sound
Tremor
Paresthesias
Headache
Muscle cramps
Nausea
Myoclonus
Diaphoresis
Sleep disturbances
Fatigue
Delirium
Anxiety
Seizures
Agitation
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plans should be made to gradually taper these medications and possibly transition to oral therapy, especially in
high-risk patients with a history of alcohol or substance dependence.1,2
The majority of critically ill patients receive sedation during their ICU stay. With proper patient assessment,
therapeutic monitoring, medication selection and titration, and de-escalation of drug therapy, clinicians can
adequately treat patient anxiety and agitation in the critical care environment while avoiding excessive or prolonged sedation that leads to deleterious outcomes. (References available upon request.)

Did You Know…
Revisions to the South Carolina Medicaid Preferred Drug List
In 2004, the South Carolina Department of Health and Human Services established a Preferred Drug List
(PDL), which serves as a component of the prior authorization (PA) program for Medicaid. Products listed on
the PDL do not require PA; however, any drug product not listed does require PA. The South Carolina Medicaid P&T Committee meets quarterly to determine any additions or deletions to the PDL. Notification of
changes are sent to providers as a Medicaid Bulletin the month following the meetings. The PDL was
amended in September to include platelet inhibitors as a therapeutic class. Other revisions have also been
made to existing therapeutic drug classes (Tables 6 and 7). Additional information and a complete list of the
Medicaid preferred drug list is available at:
http://www.dhhs.state.sc.us/Internet/pdf/Pharmacy%20PDL%20Sept%202008.pdf.
Effective with dates of service November 12, 2008, PA will be required in order for patients to receive newly
designated non-preferred products within the therapeutic classes listed in Table 7. Pharmacists should be
aware that until final implementation on November 12, soft edits
Table 6. New PDL Class - Platelet Inhibitors
will be displayed indicating the change in listing. Pharmacists are
Preferred
Non-preferred
encouraged to make prescribers and patients aware when a soft edit Aggrenox®
Dipyridamole
appears between now and implementation.
Plavix®
Ticlid®
Ticlopidine

Prescribers are encouraged to write prescriptions for the “preferred”
products rather than prescribing those
that require PA. However, if a prescriber Table 7. Changes to Existing PDL Classes
Preferred
Non-preferred
is concerned that the patient’s clinical
Oral Quinolones
status necessitates a PA-required drug
Factive® (Removed from PDL)
therapy, the prescriber should immediLevaquin® (Removed from PDL)
ately initiate a PA request. A prospective,
Long Acting Opioids
approved PA request will help to prevent
Avinza® (Removed from PDL)
rejection of prescription claims at the
Nasal Steroids
pharmacy due to the PA requirement.
®
All PA requests should be telephoned or
submitted by fax to the First Health
Clinical Call Center (866-247-118 or
866-247-1181, respectively) by the prescriber or the prescriber’s designated office personnel. Questions about Medicare
eligibility issues and Part D drug plans
should be directed to 1-800-MEDICARE.

Nasacort AQ (Removed from PDL)
Sedative Hypnotics
Lunesta® (Removed from PDL)
Ophthalmic Prostaglandins
Travatan Z® (Added to PDL)
Hematopoietics
Epogen ® (Removed from PDL)
Benzoyl Peroxide/Clindamycin Combination Products
®
Duac (Added to PDL)
Duac CS® (Added to PDL)
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FORMULARY UPDATE FOR JUNE & JULY 2008
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below. The formulary effective was September 15,
2008.
Added: Cinacalcet (Sensipar®)
Cinacalcet is a type II calcimimetic
agent approved for the treatment of
secondary hyperparathyroidism in
patients with end stage renal disease. Other treatment options for
secondary hyperparathyroidism include vitamin D analogues and
phosphate-binding agents. While
both of these medications can lower
parathyroid concentrations, they
potentially exacerbate both hyperphosphatemia and hypercalcemia.
Cinacalcet does not worsen or
cause hyperphosphatemia or hypercalcemia; however, hypocalcemia
may occur. Cinacalcet is recommended for treatment by the National Institute for Health and Clinical Excellence (NICE) in end-stage
renal patients on dialysis refractory
to prior treatment for secondary
hyperparathyroidism and should be
used as second-line therapy.
30-,60-, 90-mg tablets
Added with Restriction :
Regadenoson (Lexiscan®)
Regadenoson is indicated as a pharmacologic stress agent for radionuclide myocardial perfusion imaging
(MPI) in patients unable to undergo
adequate exercise stress.
Regadenoson, an A2A adenosine receptor agonist, produces coronary
vasodilation and increases coronary
blood flow. Regadenoson is administered as a rapid IV injection at
a fixed dose, unlike its comparator,
adenosine, which requires a weight

based 6-minute infusion, while
still producing images comparable to adenosine. Clinical trials
demonstrate absence of AV
block and bronchospasm suggesting that regadenoson might
serve as an alternative stressor to
adenosine in high-risk patients.
Regadenoson will be restricted
to patients that cannot tolerate or
have failed testing with adenosine.
0.4 mg/5 mL prefilled syringe

Line Extensions:

Change in Restriction: Oral
methotrexate (continuation of
outpatient therapy) may now be
ordered by attending physicians
double-board certified in Psychiatry/Neurology or Psychiatry/
Internal Medicine at the Institute
of Psychiatry. This will alleviate
the need for consultation to prescribe oral methotrexate by another service (ie, Rheumatology,
Neurology). However, the outpatient physician who originally
prescribed oral methotrexate for
the patient must be documented
and the pharmacy from where
the medication was last filled
must be contacted to verify the
dose/regimen.

▪

▪ Multivitamin (Nature’s Bounty
▪
▪
▪

▪

▪

MultiDay®) [tablets]
Baclofen [500 microgram/mL,
40-mL kit]
Chlorhexadine [alcohol-free
formulation]
Recombinant coagulation factor
VIIa (NovoSeven® RT)
[1-, 2-, and 5-mg vials]
Aluminum hydroxide
(Amphogel®) [320-mg/30-mL
unit-dose cups]
Carbamazepine (Tegretol®)
[200-mg/10-mL unit-dose cups]
Oxytocin [30-units/500-mL
(D5LR) infusion]

Deletions:
▪
▪
▪
▪

Multivitamin (Hexavitamin®)
ADEK chewable tablets
Chlorhexadine (alcohol-based)
Recombinant coagulation factor
VIIa (NovoSeven®)
[1.2- and 4.8-mg vials]

Drug Information Service
Monday—Friday
9:00 AM—5:30 PM
792-3896

Policy C61 Update: Medication Administration
The time allowed for medication
administration will be changed
from 1 hour around the defined
schedule to 30 minutes. This
change is based on recommendations from the Centers of Medicare and Medicaid Services
(CMS). For respiratory medications, the time allowed will remain at 60 minutes.

• Comprehensive information

concerning drug therapy
• Formulary management
• Patient-specific pharmaco-

therapy consultations
• Medication inservices
• Adverse drug reaction sur-

veillance and management
• Medication use evaluations

